Immunome Inc. (ticker: IMNM) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of IMNM's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. IMNM reported $0 in revenue and -$53.84M for the period ending 2026-03-31, with operating cash flow of -$58.64M. Cash and equivalents stood at $582.69M (up 126.2% year-over-year). Total assets of $619.79M exceed total liabilities of $31.11M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
IMNM SEC Filings
Full cached SEC EDGAR filing history for IMNM, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.